A woman sitting in her doctor’s office, waiting to get her annual health screenings. A patient lying in a hospital bed, wanting nothing more than to get better and go home. A couple waiting to find out if they are pregnant. All of these people rely on fast, accurate diagnostic testing to guide their care.
Diagnostic tests are an essential part of the healthcare system, providing important information that helps guide how patients are treated. Healthcare providers use tests to make decisions about disease prevention, diagnosis, treatment and management. In fact, 60-70 percent of critical clinical decisions are influenced by diagnostic test results.[i]
Behind the scenes of healthcare
Around the world, healthcare is evolving and these changes are impacting diagnostic testing in hospitals, laboratories and doctors' offices. For instance, global testing volumes are rising due to an aging population, the growing need to manage chronic diseases and increased access to care.[ii] Healthcare systems are also facing pressures to perform testing as efficiently as possible with limited staff and space constraints while also reducing costs.
Addressing pressing healthcare needs
To help healthcare systems address these challenges, beginning in 2016 and continuing through 2018, Abbott is introducing the Alinity™ family of next-generation systems across immunoassay, clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics. Each Alinity system includes a number of features to help institutions, clinicians and laboratorians better navigate through a pressure-packed health care environment. By addressing some of the behind-the-scenes challenges that labs and healthcare providers face, Abbott is helping doctors focus on giving patients the best possible care.
"To design AlinIQ and the Alinity Systems, we spent countless hours with our customers in the design phase to ensure that we built solutions for the issues they face every day–including higher testing volumes, a lack of staffing and space, and complex, time-intensive processes and instruments," said Dennis Gilbert, Ph.D., vice president, research and development, Diagnostics, Abbott. "Abbott is bringing meaningful innovation to diagnostic testing, elevating the role it plays in giving doctors the right information at the right time so that they may give patients the best possible care."
Want to learn more about the Alinity family of systems? Check out these resources:
"Alinity ci" Clinical Chemistry and Immunoassay Systems
"Alinity s" Blood Screening System
Please note: The Alinity suite of instruments is currently in development. Alinity launches began in 2016 and will continue into 2018.
[i] Forsman, RW. Why is the laboratory an afterthought for managed care organizations? Clinical Chemistry. 1996; 45(5): 813-16.
[ii] See page 3 of Reference: 2017 global health care outlook: Making progress against persistent challenges. Deloitte.
Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.
The website you have requested also may not be optimized for your specific screen size.
Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.
The website that you have requested also may not be optimized for your screen size.